Academic Journal
Q2Pulmonary Pharmacology and Therapeutics
About Pulmonary Pharmacology and Therapeutics
About Pulmonary Pharmacology and Therapeutics
Pulmonary Pharmacology and Therapeutics is a peer-reviewed scholarly journal published by Academic Press (United States). It focuses on Q2. Publication coverage spans 1997-2026.
Key indicators: ISSN 1094-5539, 1522-9629; H-index 87.
Understanding This Journal's Metrics
Journal metrics help researchers assess fit, but they must be interpreted in context:
- H-index (87): Strong citation impact — 87 articles cited at least 87 times each, reflecting solid influence.
Publishing in Pulmonary Pharmacology and Therapeutics
An established venue in its field. The journal welcomes solid, well-executed research. Ensure your manuscript fits the stated scope and follows author guidelines carefully.
- Scope fit: Confirm your research aligns with Q2. Off-scope manuscripts are typically desk-rejected quickly.
- Author guidelines: Follow formatting, reference style, and article-type requirements exactly — non-compliant manuscripts may be returned without review.
- Submission: Submit via the official journal website.
Is This Journal Right for Your Paper?
- Audience match: Will the journal's readers cite and build on your findings?
- Timeline: Higher-tier journals mean longer review and higher rejection risk. Balance prestige against your schedule.
- Indexing: Confirm indexing in Web of Science, Scopus, and PubMed (if biomedical) meets your institutional requirements.
- Open access needs: Check funder mandates and whether the journal offers compliant OA options.
Frequently Asked Questions
What is the ISSN of Pulmonary Pharmacology and Therapeutics?
1094-5539, 1522-9629.
Who publishes Pulmonary Pharmacology and Therapeutics?
Academic Press.
What are Pulmonary Pharmacology and Therapeutics's metrics?
H-index 87.
Where do I submit to Pulmonary Pharmacology and Therapeutics?
Via the official website.
Is Pulmonary Pharmacology and Therapeutics peer-reviewed?
Yes — it is a peer-reviewed scholarly journal indexed in major academic databases.
Source-backed journal facts
Topics in published research
Asthma and respiratory diseases; Respiratory and Cough-Related Research; Chronic Obstructive Pulmonary Disease (COPD) Research; Inhalation and Respiratory Drug Delivery; Respiratory Support and Mechanisms; Neonatal Respiratory Health Research.
OpenAlex classifies topics from published works. These topics are not the publisher’s official aims and scope.
Reported open-access list prices
3,730.00 USD; 3,490.00 EUR; 2,990.00 GBP; 462,630.00 JPY
APC list prices reported by OpenAlex, which obtains this information from DOAJ. Confirm current charges, taxes, waivers and eligibility with the publisher; this is not a fee quotation.
Source: OpenAlex source record. Retrieved 2026-10-03. Source record updated 2026-10-02. OpenAlex metrics are different from SCImago metrics and the Clarivate Journal Impact Factor.
Journal Metrics
Quartile, SJR and the listed SCImago H-index use the 2025 imported SCImago dataset. A quartile may vary by subject category. Values without a source or reporting year are unverified historical entries. Verify the current Journal Impact Factor with Clarivate or the publisher before using it.
Aims & Scope
The publisher’s official aims and scope have not yet been verified for this profile. Use the journal website to check subject fit and accepted article types before submitting.
Recent Research Articles
Latest publications matched automatically by ISSN.
Steroid-sparing strategies in respiratory diseases: efficacy and safety of current therapeutic options
Mateusz Gadzała, Aleksandra Paź, Dagmara Mirowska-Guzel
2026-12 · DOI: 10.1016/j.pupt.2026.102451TNF-α–mediated molecular switching links COPD to lung cancer: Integrated in silico and in vivo study of oxidative stress–driven disease transition
Riya Manna, Jagannath Das, Debraj Roy, Sampurna Bhattacharya et al.
2026-12 · DOI: 10.1016/j.pupt.2026.102441Belumosudil improves experimental pulmonary fibrosis via the ROCK2/Smad3/CTGF pathway
Dexin Kong, Guanghua Zhang, Zhonghong Jiang, Wanglin Jiang et al.
2026-12 · DOI: 10.1016/j.pupt.2026.102452Efficacy and safety of magnesium glycinate as add on therapy in hypomagnesemic asthma and chronic obstructive pulmonary disease patients: A randomised controlled study assessing inflammatory biomarkers
Maneesh Kumar Maddirevula, Muhasaparur G. Rajanandh, Boman Wesley
2026-12 · DOI: 10.1016/j.pupt.2026.102440Targeting pulmonary and arterial chemoreceptors via inhaled therapeutics: A novel pathway to blunt hypoxia-induced pulmonary hypertension?
Durlav Chowdhury, Surendra H. Bodakhe
2026-12 · DOI: 10.1016/j.pupt.2026.102450First-in-Human Safety and Pharmacokinetic Evaluation of Seralutinib, an Investigational Inhaled Tyrosine-protein Kinase Inhibitor for Pulmonary Hypertension
Jianke Li, Lawrence S. Zisman, Matt Cravets, Richard Aranda et al.
2026-10 · DOI: 10.1016/j.pupt.2026.102453Pharmacological Enhancement of O-GlcNAcylation Attenuates Lung Ischemia-Reperfusion Injury
Yang Jin, Yu Fu, Nan Zhang, Xuemei Jiang et al.
2026-10 · DOI: 10.1016/j.pupt.2026.102456Methodological considerations on the effectiveness of biologics in asthma-COPD overlap
Tingfang Liu, Ye Jian
2026-09 · DOI: 10.1016/j.pupt.2026.102439TROP2 as a promising therapeutic target in lung cancer: Current clinical trial landscape and future directions
Maosen Liu, Ruihang Luo, Yichen Liu, Yuxin Fan et al.
2026-09 · DOI: 10.1016/j.pupt.2026.102433PD05, a novel neutrophil elastase inhibitor, mitigates LPS-induced acute lung injury in a preclinical model
Sabita Singh, Ashish Jaiswal, Joytri Dutta, Archita Ray et al.
2026-09 · DOI: 10.1016/j.pupt.2026.102434Real-life application of the optical beta-adrenergic sweat test for people with cystic fibrosis
Karina Kleinfelder, Anca Manuela Hristodor, Giorgio Centin, Antonella Casiraghi et al.
2026-09 · DOI: 10.1016/j.pupt.2026.102437The preclinical discovery and development of depemokimab for severe eosinophilic asthma
Mario Cazzola, Vincenzo Patella, Raffaella Pagliaro, Andrea Bianco et al.
2026-09 · DOI: 10.1016/j.pupt.2026.102432Brain-derived neurotrophic factor (BDNF) signaling in respiratory disease: Mechanisms, neuroimmune crosstalk, and therapeutic implications
Entesar Yaseen Abdo Qaid, Idris Long
2026-09 · DOI: 10.1016/j.pupt.2026.102435Editorial Board
2026-09 · DOI: 10.1016/s1094-5539(26)00038-6m6A reader IGF2BP2 mediates airway remodeling by stabilizing Dixdc1 in asthma pathogenesis
Xiao-Mang Li, Bi-Wen Mo, Yan Gao, Yun-Xiang Chen et al.
2026-09 · DOI: 10.1016/j.pupt.2026.102438Effects of anumigilimab, an anti–G-CSF receptor mAb, after segmental LPS challenge: A Phase 1b trial in healthy volunteers
Jens M. Hohlfeld, Meike Müller, Philipp Badorrek, Laurent B. Nicolas et al.
2026-09 · DOI: 10.1016/j.pupt.2026.102436Pulmonary safety of Staccato alprazolam in healthy participants and participants with mild asthma: Phase 1, randomized, double-blind, placebo-controlled trial
S. David Miller, Craig F. LaForce, Laura Barlow, Shikiko Watanabe et al.
2026-06 · DOI: 10.1016/j.pupt.2026.102411Evodiamine protects against lung ischemia–reperfusion injury by attenuating SYK-associated TLR4/NLRP3 inflammasome activation and ferroptosis-related injury signatures
Wei Peng, Baiping Ge, Rui Zhang, Yunen Liu et al.
2026-06 · DOI: 10.1016/j.pupt.2026.102421Nicotinamide N-oxide alleviates sepsis-induced acute lung injury by inhibiting ferroptosis through activation of the SIRT1/AKT signalling pathway
Shujuan Liu, Mian Fu, Xiguang Liu, Yichen Jin et al.
2026-06 · DOI: 10.1016/j.pupt.2026.102419Evaluation of the effect of modulator therapies on medication complexity in adult cystic fibrosis patients
Esen Deniz Akman Ar, Nadir Yalçın, Uğur Balaban, Oğuz Karcıoğlu et al.
2026-06 · DOI: 10.1016/j.pupt.2026.102420Reviews
Community Reviews
Version History
October 9, 2026 at 10:14 pm
October 2, 2026